<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014248</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068522</org_study_id>
    <secondary_id>DMS-0005</secondary_id>
    <secondary_id>ATP-DMS-0005</secondary_id>
    <secondary_id>NCI-G01-1923</secondary_id>
    <nct_id>NCT00014248</nct_id>
  </id_info>
  <brief_title>Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study And Pharmacokinetics Of Adenosine 5'- Triphosphate (ATP) When Administered By Intravenous Infusion On A Multiple Weekly Dose Schedule To Patients With Advanced Malignancies (Solid Tumors)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Adenosine triphosphate may decrease weight loss and improve muscle strength in&#xD;
      patients with advanced solid tumors.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of adenosine triphosphate in controlling&#xD;
      loss of weight and loss of muscle mass in patients who have advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the individualized maximum tolerated dose of adenosine triphosphate in&#xD;
           patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine the effect of this regimen on quality of life of these patients.&#xD;
&#xD;
        -  Determine the influence of this regimen on cancer cachexia in terms of weight change,&#xD;
           percentage of body fat, voluntary muscle strength, and plasma markers in these patients.&#xD;
&#xD;
        -  Determine the effect of this regimen on tumor burden in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive adenosine triphosphate (ATP) IV over 8 hours on day 0. Treatment repeats&#xD;
      weekly for a total of 8 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Each patient receives escalating doses of ATP until the individual maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which the patient&#xD;
      experiences at least grade 3 (at least grade 2 cardiac ischemia or arrhythmia) toxicity.&#xD;
&#xD;
      Weight is measured at baseline and at weeks 1-8, 10, and 13. Percentage of body fat and&#xD;
      skeletal muscle strength is measured at baseline and at weeks 2, 4, 8, 10, and 13.&#xD;
&#xD;
      Quality of life is assessed at baseline and at weeks 2, 4, 8, 10, and 13.&#xD;
&#xD;
      Patients are followed at weeks 10 and 13.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 13-24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Cachexia</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adenosine triphosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumor that is not curable by&#xD;
             conventional therapy&#xD;
&#xD;
          -  Brain metastases allowed if adequately controlled with radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT and SGPT no greater than 3 times normal&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  BUN no greater than 25 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Adequate cardiovascular function&#xD;
&#xD;
          -  No congestive heart failure (New York Heart Association class III or IV heart disease)&#xD;
&#xD;
          -  No angina pectoris AND/OR&#xD;
&#xD;
          -  No significant arrhythmia&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No clinically significant ischemic cardiac disease currently under treatment&#xD;
&#xD;
          -  No clinically significant conduction system disease in the absence of a pacemaker&#xD;
             (e.g., sick sinus syndrome, or second or third degree atrioventricular block)&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Adequate pulmonary function&#xD;
&#xD;
          -  No clinical evidence of acute chronic obstructive pulmonary disease&#xD;
&#xD;
          -  FEV1 at least 50% predicted&#xD;
&#xD;
          -  Arterial oxygen tension at least 90% by pulse oximetry and on breathing room air&#xD;
&#xD;
          -  No asthma OR&#xD;
&#xD;
          -  No evidence of more than 20% reversibility in FEV1 with albuterol therapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of severe adverse reaction to adenosine&#xD;
&#xD;
          -  No uncontrolled medical illness&#xD;
&#xD;
          -  No average daily pain scores of at least 5 on a simple Visual Analogue Self pain&#xD;
             assessment (0-10) scale&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior investigational therapy&#xD;
&#xD;
          -  At least 14 days since prior long-term theophylline, dipyridamole, or&#xD;
             dipyridamole/aspirin therapy&#xD;
&#xD;
          -  No concurrent long-term theophylline, dipyridamole, or dipyridamole/aspirin therapy&#xD;
&#xD;
          -  No concurrent maintenance anti-anginal drug therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel D. Lewis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>July 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2003</study_first_posted>
  <last_update_submitted>March 15, 2013</last_update_submitted>
  <last_update_submitted_qc>March 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>cachexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

